We are pleased to announce that the virtual 15th Annual European Life Sciences CEO Forum(ELSF) will take place on the 1st-2nd of March 2022 and be part of the digital Sachs Spring Life Sciences Week, that will also incorporate the 3rd Annual European HealthTech CEO Forum.
IMPORTANT UPDATE Please note, due to the Omicron variant and new Swiss quarantine regime for incoming arrivals we have decided to suspend in-person registrations for the Sachs Life Science Week. Meanwhile, we will be planning the event in digital format and will provide the usual stimulating programme, company showcases, and the usual networking opportunities delivered via the video online meeting system.
Back for its 15th Annual Edition, this global bio-pharma industry event will address the main challenges for 2022, including investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors.
The main programme for the 15th AnnualELSF is spread throughout 2 days (1st-2nd of March) and will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 12 hours of high-level speeches and panel discussions. In addition, there will be 45+ presentations by globally established public, private, emerging and seed companies who offer innovation solutions and are seeking investment and partnering opportunities. We anticipate 400+delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, bankers and advisors.
The virtual meetings will take place from the 28th February to 4th of March. Moreover, the system will be open for 12 hours a day and we expect 1500+ meetings completed over 5 days. The conference will be held in the Central European Time Zone. The digital event will consist of:
BioCapital & Investment Day (Tuesday, 1st of March)
State of the Industry Panel
Pandemic Response Panel
VC, Private Equity Funds Panel
Platform Technologies & Novel Therapeutics Panel
Biotech Capital Markets Panel
Advances in Gene & Cell Therapies Panel
Early Stage Innovation & Investment Panel
Rising Stars Session
Bio-Pharma Partnering & Therapeutics Day (Wednesday, 2nd of March)
China BioPartnering & Investment: Bringing Chinese Innovation to Global Markets Panel
Pharma M&A and Partnering Panel
Immuno-Oncology BD & Partnering Panel
Advances in Immuno-Oncology Panel
Recent Advances in Alzheimer’s & Other Neurodegenerative Disorders Panel
Biotech Meets FoodTech Panel
Online Virtual Meetings (28th February - 4th of March)
Confirmed Chairs & Speakers Include:
Alexandre Bastos, Head of Front End Innovation, Givaudan
Andrea Carfi, Chief Scientific Officer, Infectious Disease, Moderna, Inc.
Andreas Hohn, Director of Transaction Excellence, Roche Partnering, F. Hoffmann-La Roche Ltd.
Andrew Allen, Co-Founder, President & CEO, Gritstone Bio, Inc.
Aram Mangasarian, CEO, NOXXON Pharma NV
Bibhash Mukhopadhyay, Founder & Managing Partner, Sound Bioventures Management AB
Christina Hertel, Senior Program Manager – Gold Track, EIT Health e.V.
Corinne Venot, Executive Director, Business Development, BeiGene Ltd.
Daniel Teper, Co-Founder, Chairman & CEO, Cytovia Therapeutics Inc.
Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
Free access to view live sessions is provided to all interested and qualified participants, this will allow us to provide a higher exposure for participating companies. Additionally, you can purchase a Video on Demand pass, which will allow you to view not only live sessions, but also recordings of all sessions, in addition to speaker and company profiles and their presentations.
The Online Meeting System will open on the 14th of February for uploading profiles and sending meeting invites. Meetings will take place from the 28th February to 4th of March. The system will allow you to have a secure audio/video call, as well as an option to present slides using the screen share function. Meetings will last for 30 minutes. The Basic Online Meeting System Access, with 10 meeting invitations, will be provided complimentary for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however organizer has the discretion to reject passes. Other participants may consider purchasing Basic, Advanced or Premium Access with an option for a live spotlight or a pre-recorded showcase presentation. The number of meeting invites defines how many requests can be sent. If a meeting invite is declined, you will receive a meeting credit back that can be reused. The number of invites does not restrict how many meeting invitations you can receive. If we are permitted to deliver a hybrid event you will have an option to register and attend two days in-person, which will include a mix of live content, which will be broadcasted, and pre-recorded content streamed live, in addition to pre-arranged in-person & virtual meetings and a reception. More information and option will be announced in January.
Gain additional exposure to high-level decision makers by presenting at the forum, which offers excellent opportunities to showcase your company’s investment and partnering offering. This typically includes technology and financial highlights. This adds to the news flow from the forum and generates greater interest in meetings from other delegates.
For those interested to join the companies’ showcases, there is an option to purchase either a 10 or 20 minute presentation, which will be pre-recorded in advance and available to all registered attendees before, during and after the conference on the event’s portal. There is also a limited number of 20-minute Spotlight presentations with additional branding to provide even higher exposure, which will be broadcasted live during the main programme after a relevant panel discussion and available on demand afterwards. Start-up companies, which are looking for seed financing may also apply for a 5 or 10 minute showcase option. The Sachs team can assist with the pre-recording of the presentation or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.
Make connections, engage in conversation, and exchange knowledge with key decision-makers, who are eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at Sachs Spring Life Sciences Week is an effective way to gain leads, introduce new products and services, expand sales and build relationships.
The virtual exhibition package includes a dedicated virtual page, where we can: upload your branded company’s profile; list ways to reach you; share video or images about services you provide; have files ready for download, if you wish to share any additional information with potential clients.
There are a limited number of sponsorship opportunities for the forum, which includes speaking, advertising and branding options. Sponsors typically include investment banks and funds, large pharma, technology companies and service providers, including Stock Exchanges, IR companies, CROs, international lawyers and consulting companies. Tailored packages are available upon request. You can view latest event’s sponsors here.
To learn more about presenting, exhibition or sponsorship opportunities, please fill in registration form or contact us at SachsTeam@SachsForum.com or by phone + 44 (0)203 463 4890.
Investors & Analysts attending:
3B Future Health Ventures 6 Dimensions Capital Abingworth LLP Additio Investment Group Aescuvest International Aglaia Oncology Funds Allele Capital Partners Alpha Blue Ocean Ltd. ALSA Ventures Amadeus Capital Partners Apeiron Investments Apollo Health Ventures Aqua Partners LLC ARCH Venture Partners Arix Bioscience plc Asabys Partners Ascend Capital Partners Asklepios Advisors ATGN Consulting ATP (Apple Tree Partners) AurorA Science Srl AVANTECA Partners AG BaseLaunch Bergmann zur Hausen & Cie. GmbH BERNINA BioInvest Ltd. Big Pi Ventures SCSp BIMA Capital, LLC Bio Medi Gene Ventures BioMedPartners AG Bionova Capital SCR SA BioPharma Advisory Bioqube Ventures BIOSTART Consulting GmbH BioValley Basel & Suterscience, LLC BioVeda China Fund (BVCF) Bootstrap Europe SCSP Bpifrance Bradley Woods & Co. Ltd Brandon Capital Partners Breslin AG Brightlands Venture Partners Brookline Capital Markets BROTHERS & Partners Europe BTIG, LLC Caixa Capital Risc Catalytic Impact Foundation, Inc. Cello Health BioConsulting Claris Ventures Clave Mayor S.G.E.I.C., S.A. coparion GmbH & Co. KG CTI Life Sciences Cukierman & Co. Investment House, FoodTech & Agritech Cukierman & Co. Life Sciences Debiopharm Innovation Fund SA Deep Science Ventures Deutsche Bank Digital Networks PLC Dorset Capital LLC Droege Group E.Gutzwiller & Cie, Banquiers Eight Roads Ventures Eir Ventures Partners AB Epidarex Exeed Limited ESC Advisors European Investment Fund Ferghana Partners LLP Flerie Invest AB Forbion Forty51 Ventures Fountain Healthcare Partners Ltd Fraser Finance LLP FutuRx Ltd. GCF Family Office GEM Generation Fund Life Sciences Fund I Gimv NV Global Founders Capital Global Health Investment Corporation GLSV GmbH iL | MicroCures Inc | Neurevo GmbH Hadean Ventures HBM Partners AG HealthCap HealthCare Royalty Partners Hestia Investments Ltd. High-Tech Gründerfonds Management GmbH IAG - Italian Angels for Growth IAG, Image Analysis Group IBB Beteiligungsgesellschaft GmbH ICF Consult Switzerland Illumina Ventures Inbio Ventures Indaco Venture Partners SGR SpA Independent R.B. Independent R.M. Industrifonden INKEF Capital BV Inveready Asset Management Invivo Capital Partners, S.G.E.I.C, S.A. IPF Partners J.P. Morgan Jefferies International Ltd. Jeito Capital Johnson & Johnson Innovation – JJDC, Inc. Kempen & Co KIZOO Technology Capital GmbH Kreos Capital Kurma Partners Landmark Angels, Inc. Landmark BioVentures AG LifeArc Ventures LifeCare Partners GmbH LifeLink Ventures LifeSci Capital LLC LifeSci Consulting Long State Investments Longliv Ventures LSFA & BRESLIN AG